teaser
French-based biotechnology company Novasep has installed and validated a new industrial HPAI
 (highly potent active ingredient) manufacturing plant in its facility at Le Mans, France.
The move follows the establishment of a second kilo-lab for highly potent substance synthesis and
 purification.
In a press release, the company said the 
€8m investment had been made to meet growing demand for
 multipurpose chemistry and purification of highly potent molecules in a highly confined current Good Manufacturing Practices environment.
The firm said the value of combined investments at the Le Mans site was now €50m.
Novasep provides synthesis support services for highly potent molecules, from early stage phases of development through to commercial 
quantities.
